Case File
efta-01973209DOJ Data Set 10OtherEFTA01973209
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01973209
Pages
3
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
Fenn, Patric
From:
Jeffrey Epstein
Sent
Sun 5/19/2013 4:58:45 PM
Subject: Re:
I have not seen the dp valuation , but the expectation of its use must be in the calculation??
On Sun, May 19, 2013 at 12:56 PM, Fenn, Patrick
wrote:
The TRA payments made now are treated as additional purchase price for the 2007 purchased
partnership interests that in turn produce more amortization and imputed interest expense.
Capital loss on early termination of TRA for unexchanged units might give rise to a deferred tax asset
for accounting purposes, but then probably only if there was some expectation that it could be
utilized.
From: Jeffrey Epstein [mailto:jeevacationeamail.com]
Sent: Sunday, May 19, 2013 12:52 PM
To: Fenn, Patrick
Subject: Re:
how do they currently report the payments, as you are rightly concerned about a 750 capital
loss
On Sun, May 19, 2013 at 12:22 PM, Fenn, Patrick
wrote:
You mean for financial accounting purposes?
From: Jeffrey Epstein [mailto:teevacationaamaitcom]
Sent: Sunday, May 19, 2013 12:01 PM
To: Fenn, Patrick
Subject:
if the co reports the transaction with the tra, how do they record the fact that they will pay less
taxes for the next 15 years. in exchange
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
EFTA_R1_00457266
EFTA01973209
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any pan thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail,com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Notice Requirement: This communication is not given in the form of
a covered opinion, within the meaning of Circular 230 issued by the United States
Secretary of the Treasury. Thus, we are required to inform you that you cannot
rely upon any tax advice contained in this communication for the purpose of
avoiding United States federal tax penalties. In addition, any tax advice
contained in this communication may not be used to promote, market or recommend a
transaction to another party.
The information contained in this e-mail message is intended only for the personal
and confidential use of the recipient(s) named above. If you have received this
communication in error, please notify us immediately by e-mail, and delete the
original message.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Notice Requirement: This communication is not given in the form of
a covered opinion, within the meaning of Circular 230 issued by the United States
Secretary of the Treasury. Thus, we are required to inform you that you cannot
rely upon any tax advice contained in this communication for the purpose of
avoiding United States federal tax penalties. In addition, any tax advice
contained in this communication may not be used to promote, market or recommend a
transaction to another party.
The information contained in this e-mail message is intended only for the personal
and confidential use of the recipient(s) named above. If you have received this
communication in error, please notify us immediately by e-mail, and delete the
original message.
EFTA_R1_00457267
EFTA01973210
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA_R1_00457268
EFTA01973211
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
jeevacationeamail.comEmail
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.